Previous 10 | Next 10 |
- Tisotumab Vedotin in Combination with Carboplatin Showed Encouraging, Durable Anti-Tumor Activity as First-Line Treatment - - Tisotumab Vedotin in Combination with Pembrolizumab Showed Encouraging, Durable Anti-Tumor Activity in Previously Treated Patients - Seag...
Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...
After the recent era of value expansion due to the pandemic and fiscal policy, the use of unbiased rankings may allow for long-term success. As valuations come back down to historical levels, as very few would claim they will stay elevated perpetually, holding the right stocks will be...
The biotech industry is making considerable progress in developing viable drugs and therapies for treating several critical diseases with the integration of advanced technologies. But although rising investments and breakthroughs in clinical trials make the industry’s prospects bright,...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September
Media Release Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary efficacy of epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) published in The Lancet Results als...
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet - Phase 1/2 first-in-human (FIH) dose escalation and cohort expansion trial evaluating safety and preliminary...
Bolt has built out a next-generation immunotherapy platform to design biologics for cancers that are not accessible for the current standard-of-care. The company's lead asset, BDC-1001, is expected to complete phase 1 clinical trials later this year creating a window for an opportunis...
Genmab currently has aided and/or partnered in the development of four FDA approved monoclonal antibody therapies. While not the owners, developers, or manufacturers of most of these therapies, the company earns money via licensing of their novel and innovative technology. This wi...
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q2 2021 Earnings Call Aug 11, 2021 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...